{"gene":"GDF15","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1999,"finding":"MIC-1/GDF15 is synthesized as a 62-kDa intracellular precursor protein that is cleaved by a furin-like protease and secreted as a 25-kDa disulfide-linked dimeric protein.","method":"Protein expression analysis, biochemical characterization of cleavage and dimerization","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical characterization in a single lab with multiple orthogonal methods (size analysis, protease identification, secretion assay)","pmids":["9886240"],"is_preprint":false},{"year":1997,"finding":"GDF15/PLAB inhibits the proliferation of primitive hematopoietic progenitors, demonstrating a direct biological activity.","method":"In vitro proliferation assay with hematopoietic progenitors","journal":"Biochimica et biophysica acta","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single functional assay, limited mechanistic detail in abstract","pmids":["9375789"],"is_preprint":false},{"year":2017,"finding":"GDNF family receptor α-like (GFRAL) is the high-affinity receptor for GDF15; GDF15 binds GFRAL with high affinity and requires GFRAL to elicit intracellular signaling through the co-receptor RET. GFRAL expression is restricted to neurons of the area postrema and nucleus of the solitary tract in the hindbrain. Genetic deletion of GFRAL abolishes GDF15-induced reductions in food intake and body weight in mice.","method":"Receptor binding assays, co-receptor identification (RET), GFRAL knockout mice, in vivo pharmacology in mice and nonhuman primates","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — independently replicated by four labs simultaneously (PMIDs 28846097, 28846098, 28846099, 28953886) using binding assays, knockout models, and in vivo pharmacology","pmids":["28846097","28846098","28846099","28953886"],"is_preprint":false},{"year":2017,"finding":"GDF15 activates neurons in the area postrema and nucleus tractus solitarius via GFRAL, which then triggers activation of neurons in the parabrachial nucleus and central amygdala as part of an 'emergency circuit' regulating feeding responses under stress. GFRAL knockout mice are resistant to chemotherapy-induced anorexia and body weight loss.","method":"Neuronal activation mapping, GFRAL knockout mice, chemotherapy-induced anorexia model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with defined phenotypic readout, neural circuit mapping, replicated across multiple labs","pmids":["28953886"],"is_preprint":false},{"year":2017,"finding":"GDF15 delays gastric emptying and activates area postrema neurons, consistent with a gut-brain axis role in regulating energy intake. Crystal structure analysis of GDF15 informed structure-guided design of Fc fusion proteins with extended half-life.","method":"Gastric emptying assay, area postrema neuron activation imaging, GDF15 crystal structure analysis","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — crystal structure combined with functional in vivo assays in a single lab","pmids":["29046435"],"is_preprint":false},{"year":2019,"finding":"Metformin increases circulating GDF15 levels, with GDF15 expression increasing predominantly in the distal intestine and kidney. Metformin's effects on body weight and energy balance are absent in GDF15 knockout mice and GFRAL knockout mice, and are reversed by a GFRAL-antagonist antibody, demonstrating that the GDF15-GFRAL axis is required for metformin-induced weight loss.","method":"Randomized controlled trials (human), GDF15 and GFRAL knockout mice, GFRAL-antagonist antibody treatment, tissue-specific expression analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including human RCTs, genetic knockout models, and pharmacological antagonism in a single comprehensive study","pmids":["31875646"],"is_preprint":false},{"year":2019,"finding":"GDF15 expression is regulated by the integrated stress response and is induced in selected tissues by sustained high-fat feeding or dietary amino acid imbalance. Pharmacological GDF15 administration triggers conditioned taste aversion in mice, indicating an aversive component to its anorectic action.","method":"Mouse dietary models, conditioned taste aversion assay, tissue expression analysis","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple dietary models and behavioral assay in a single lab","pmids":["30639358"],"is_preprint":false},{"year":2020,"finding":"A GFRAL-antagonist monoclonal antibody (3P10) inhibits RET signaling by preventing the GDF15-driven interaction of RET with GFRAL on the cell surface. GDF15-GFRAL-RET pathway activation induces lipid metabolism gene expression in adipose tissue; peripheral chemical sympathectomy and loss of adipose triglyceride lipase protect mice from GDF15-induced weight loss, revealing a peripheral sympathetic-lipolytic axis downstream of GFRAL.","method":"Antagonistic antibody treatment, chemical sympathectomy, adipose triglyceride lipase knockout mice, gene expression analysis in adipose tissue, tumor-bearing mouse models","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genetic and pharmacological approaches with defined molecular mechanism in a single rigorous study","pmids":["32661391"],"is_preprint":false},{"year":2014,"finding":"Transgenic overexpression of human NAG-1/GDF15 in mice increases thermogenic gene expression (UCP1, PGC1α, and others) in brown adipose tissue and lipolytic gene expression (Adrb3, ATGL, HSL) in white and brown adipose tissue, resulting in increased energy expenditure and resistance to diet-induced obesity without reducing food intake.","method":"Transgenic mouse overexpression model, high-fat diet challenge, gene expression analysis (thermogenic and lipolytic genes), xenograft model","journal":"International journal of obesity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic overexpression and xenograft model with defined gene expression readouts in a single lab","pmids":["24531647"],"is_preprint":false},{"year":2021,"finding":"GDF15 potently activates the hypothalamic-pituitary-adrenal (HPA) axis in mice and rats via GFRAL; a blocking antibody to GFRAL completely prevented the corticosterone response to GDF15 administration. In wild-type mice, endogenous GDF15 is required for HPA axis activation in response to genotoxic or endoplasmic reticulum toxins (which do not provoke cytokine responses), as shown by the absence of this response in Gdf15-/- mice.","method":"GDF15 administration with GFRAL-blocking antibody, Gdf15 knockout mice, corticosterone measurement, multiple stress models (LPS, genotoxic, ER toxins)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function and pharmacological blockade with multiple orthogonal stress models and defined endocrine readout","pmids":["34187898"],"is_preprint":false},{"year":2021,"finding":"PPARβ/δ activation increases GDF15 levels via an AMPK-p53 pathway, and GDF15 in turn sustains AMPK activation; the metabolic effects of PPARβ/δ activation (glucose tolerance improvement, fatty acid oxidation, ER stress reduction, AMPK activation) are abrogated by GDF15 neutralizing antibody or in Gdf15-/- mice.","method":"GDF15 neutralizing antibody, Gdf15 knockout mice, pharmacological PPARβ/δ activation, AMPK activity assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological epistasis with defined pathway placement in a single lab","pmids":["34380027"],"is_preprint":false},{"year":2021,"finding":"GDF15 combined with leptin causes greater weight and adiposity loss in obese mice than either treatment alone. GFRAL-expressing neurons in the hindbrain are extensively connected with leptin receptor (LepR)-expressing neurons; LepR knockdown in the NTS reduces GDF15-mediated AP neuronal activation, indicating that leptin signaling in the hindbrain potentiates GDF15's metabolic actions.","method":"Combined GDF15 and leptin infusion in obese mice, leptin receptor knockdown in NTS, hindbrain neuronal activation mapping, leptin-deficient ob/ob mice and competitive leptin antagonist","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple complementary genetic and pharmacological approaches with defined neural circuit readout in a single lab","pmids":["37433299"],"is_preprint":false},{"year":2023,"finding":"GDF15 counteracts adaptive thermogenesis (compensatory reduction in energy expenditure during caloric restriction) by maintaining energy expenditure through a GFRAL-β-adrenergic-dependent signaling axis that increases fatty acid oxidation and calcium futile cycling in skeletal muscle of mice.","method":"Recombinant GDF15 treatment, caloric restriction models, β-adrenergic signaling analysis, fatty acid oxidation and calcium futile cycling assays in skeletal muscle","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal mechanistic assays (fatty acid oxidation, calcium cycling, β-adrenergic pathway) with defined GFRAL-dependent mechanism","pmids":["37380764"],"is_preprint":false},{"year":2023,"finding":"Metformin increases plasma GDF15 levels by upregulating GDF15 synthesis specifically in the kidney. Kidney-specific knockdown of GDF15 expression, as well as area postrema-specific knockdown of GFRAL, negated the ability of metformin to lower food intake and body weight in rats.","method":"Tissue-specific AAV-mediated knockdown of GDF15 in kidney and GFRAL in area postrema, plasma GDF15 measurement, food intake and body weight assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific genetic knockdown at two anatomical sites with defined functional readout","pmids":["37060902"],"is_preprint":false},{"year":2023,"finding":"Ketogenic diet activates hepatic PPARγ, which directly binds to the regulatory region of Gdf15, increasing its transcription in hepatocytes. Elevated circulating GDF15 is required for ketogenic diet-mediated weight loss via GFRAL signaling; GDF15- or GFRAL-deficient mice do not lose weight on KD.","method":"PPARγ chromatin immunoprecipitation, hepatocyte-specific AAV8 Gdf15 knockdown, GDF15 and GFRAL knockout mice, hepatic Pparγ knockout mice, recombinant GDF15 rescue experiments","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP demonstrating direct PPARγ binding to Gdf15 regulatory region, multiple genetic models with rescue experiments","pmids":["38056430"],"is_preprint":false},{"year":2022,"finding":"CNOT6L deadenylase regulates GDF15 expression post-transcriptionally; CNOT6L inhibition stabilizes hepatic Gdf15 mRNA, increasing circulating GDF15 levels which act on the hindbrain to suppress appetite.","method":"CNOT6L inhibition, mRNA stability assay, serum protein measurement, food intake assay","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mRNA stabilization mechanism with functional in vivo readout in a single lab","pmids":["35385705"],"is_preprint":false},{"year":2019,"finding":"β-Arrestin1 (ARRB1) interacts with GDF15 precursor (pro-GDF15) and facilitates transportation of pro-GDF15 to the Golgi apparatus for cleavage and maturation. ARRB1 deficiency impairs GDF15 maturation and accelerates steatohepatitis development.","method":"Co-immunoprecipitation (ARRB1-GDF15 interaction), Arrb1 knockout mice, pro-GDF15 overexpression rescue experiments, recombinant GDF15 treatment","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP demonstrating physical interaction plus genetic knockout with rescue, single lab","pmids":["31857195"],"is_preprint":false},{"year":2021,"finding":"GDF15 promotes generation of peripherally derived inducible Treg cells and enhances suppressive function of natural Treg cells by interacting with CD48 on T cells, which downregulates STUB1 (an E3 ligase that mediates FOXP3 protein degradation), thereby stabilizing FOXP3 and promoting immunosuppression in HCC.","method":"Co-immunoprecipitation (GDF15-CD48 interaction), mass spectrometry, chromatin immunoprecipitation, Gdf15 knockout mouse models, flow cytometry, RNA sequencing","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying CD48 as receptor plus downstream mechanistic pathway with multiple methods, single lab","pmids":["34489334"],"is_preprint":false},{"year":2020,"finding":"GDF15 stimulates melanogenesis in melanocytes through MITF/tyrosinase upregulation via β-catenin signaling, as demonstrated by co-culture experiments with GDF15-overexpressing or GDF15-knockdown fibroblasts.","method":"Fibroblast-melanocyte co-culture, GDF15 lentiviral overexpression and shRNA knockdown, melanogenesis assay, ex vivo skin culture","journal":"The Journal of investigative dermatology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — co-culture experiment with defined signaling pathway, single lab, no receptor identification","pmids":["32416083"],"is_preprint":false},{"year":2018,"finding":"GDF15 promotes cervical cancer cell proliferation via the PI3K/AKT and MAPK/ERK signaling pathways, and GDF15 forms a protein complex with ErbB2 in cervical cancer cells as identified by immunoprecipitation. C-myc trans-activates GDF15 expression by binding E-box motifs in the GDF15 promoter.","method":"Immunoprecipitation (GDF15-ErbB2 complex), chromatin immunoprecipitation (C-myc binding to GDF15 promoter), western blotting, MTT assay, in vivo tumor formation","journal":"Journal of experimental & clinical cancer research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP with limited mechanistic follow-up, single lab, GFRAL-independent mechanism proposed without full validation","pmids":["29636108"],"is_preprint":false},{"year":2016,"finding":"GDF15 promotes epithelial-mesenchymal transition (EMT) and metastasis in colorectal cancer by binding to TGF-β receptor and activating Smad2 and Smad3 signaling pathways.","method":"Recombinant GDF15 treatment, TGF-β receptor binding, Smad2/3 phosphorylation assay, in vitro metastasis assays, in vivo xenograft model","journal":"Oncotarget","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, receptor binding claim without full biochemical validation; TGF-β contamination issue noted in PMID 29161287 may confound some GDF15-TGFβR findings","pmids":["26497212"],"is_preprint":false},{"year":2018,"finding":"GDF15 inhibits lung fibroblast growth and activation by inactivating the TGF-Smad pathway; GDF15 administration alleviates pulmonary fibrosis in mouse models.","method":"Primary fibroblast culture, epithelial cell-conditioned media fractionation, TGF-Smad pathway signaling analysis, mouse lung fibrosis model","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway analysis without full mechanistic dissection, note potential TGF-β contamination concern","pmids":["29724997"],"is_preprint":false},{"year":2022,"finding":"Recombinant GDF15 stimulates α-smooth muscle actin (αSMA) expression in normal human lung fibroblasts, and this fibroblast activation is mediated through the ALK5 (activin receptor-like kinase 5) receptor, not GFRAL, suggesting a GFRAL-independent mechanism in peripheral fibrosis.","method":"Recombinant GDF15 treatment of lung fibroblasts, αSMA expression assay, ALK5 receptor inhibitor experiments, 3D spheroid assay, in vivo bleomycin fibrosis model with GDF15 neutralization","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological receptor dissection (ALK5) in vitro combined with in vivo neutralization, single lab with multiple methods","pmids":["35993367"],"is_preprint":false},{"year":2021,"finding":"AMPK mediates energetic stress-induced GDF15 expression in mouse liver; direct activation of AMPK β1-containing complexes by A769662 increases hepatic Gdf15 expression and circulating GDF15 independently of ER stress, an effect absent in AMPKβ1-/- mice.","method":"AMPKβ1 knockout mice, direct AMPK activators (AICAR, R419, A769662), CHOP knockout mice, hepatic Gdf15 expression and circulating GDF15 measurement","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function (AMPKβ1-/-) with pharmacological dissection of ER-stress independence, single lab","pmids":["33337559"],"is_preprint":false},{"year":2022,"finding":"GDF15 upregulation by metformin is AMPK-dependent, and GDF15 in turn is required for full AMPK activation by metformin in liver and skeletal muscle independently of CNS/GFRAL signaling, revealing a positive feedback loop between AMPK and GDF15.","method":"Gdf15 knockout mice, Gdf15 siRNA knockdown in cultured hepatocytes and myotubes, AMPK activity assays, metformin treatment","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and siRNA-based loss of function with enzyme activity assays, single lab","pmids":["36435271"],"is_preprint":false},{"year":2024,"finding":"GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway; Gdf15-/- mice show overactivated TGF-β1/SMAD3 signaling, reduced hepatic AMPK activity, elevated gluconeogenesis and fibrosis, and recombinant GDF15 reverses these effects in hepatocytes independently of GFRAL.","method":"Gdf15 knockout mice, recombinant GDF15 treatment, pharmacological SMAD3 inhibition, primary hepatocyte culture, AMPK and SMAD3 phosphorylation assays","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with recombinant rescue and pharmacological epistasis, single lab","pmids":["38176644"],"is_preprint":false},{"year":2022,"finding":"GDF15 knockdown in cancer cells decreases SLC7A11 (system Xc- component) expression, promotes erastin-induced ferroptosis, and reduces extracellular glutamate, intracellular GSH, while increasing lipid ROS levels, indicating GDF15 promotes ferroptosis resistance through SLC7A11 upregulation.","method":"GDF15 siRNA knockdown, erastin-induced ferroptosis assay, SLC7A11 expression analysis, lipid ROS measurement, GSH quantification","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell line, no receptor or upstream mechanism identified","pmids":["32209255"],"is_preprint":false},{"year":2021,"finding":"In the asthma context, Wnt pathway activation downstream of Notch4 in Treg cells induces GDF15 expression, and GDF15 produced by Treg cells activates group 2 innate lymphoid cells (ILC2s), creating a feed-forward mechanism for aggravated airway inflammation.","method":"Notch4 conditional knockout, Wnt pathway inhibition, GDF15 expression analysis in Treg cells, ILC2 activation assay","journal":"Nature immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic pathway dissection with defined cellular mechanism, single lab","pmids":["32929274"],"is_preprint":false},{"year":2019,"finding":"GDF15 apoptotic and cytotoxic effects in A549 lung cancer cells depend on TGFBR2 expression; TGFBR2 silencing blocks GDF15-induced cytotoxicity, apoptosis, caspase-9 and caspase-3 activation, and ERK1/2/p38 MAPK modulation.","method":"TGFBR2 siRNA knockdown, GDF15 overexpression, caspase activation assay, annexin V/PI flow cytometry, ERK/p38 phosphorylation","journal":"Cell biochemistry and function","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single cell line, single lab; TGFBR2 as a GDF15 receptor is contested (TGF-β contamination issue noted in PMID 29161287)","pmids":["31172564"],"is_preprint":false},{"year":2022,"finding":"Pharmacological GDF15 suppresses voluntary wheel running activity (exercise motivation) and feeding via GFRAL-dependent mechanisms, but physiologically induced GDF15 by exercise does not affect appetite or exercise motivation despite reaching similar circulating levels.","method":"Recombinant GDF15 administration, GFRAL antagonism, voluntary wheel running assay, exercise intervention in mice and humans, food intake measurement","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — four independent human studies plus mouse pharmacology and GFRAL genetic control, single lab group","pmids":["33589633"],"is_preprint":false},{"year":2022,"finding":"GDF15 and semaglutide reduce food intake and body weight through largely distinct mechanisms: semaglutide amplifies satiation signals (CCK, ingested food) and inhibits AgRP neurons, while GDF15 induces visceral malaise but does not affect feeding motivation or CCK signal processing; combined treatment produces additive weight loss without enhanced malaise.","method":"Progressive ratio operant paradigm, CCK potentiation assay, pica/kaolin intake assay, conditioned food aversion test, fibre photometry of AgRP neurons in vivo","journal":"Diabetes, obesity & metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple behavioral and neural circuit assays distinguishing GDF15 vs. semaglutide mechanisms, single lab","pmids":["35129264"],"is_preprint":false},{"year":2023,"finding":"GDF15 produced in white adipose tissue macrophages (M2-like) mediates adrenaline/β-adrenergic-induced anxiety-like behavior; genetic deletion of adipose triglyceride lipase or β-adrenergic receptors blocks β-adrenergic-induced GDF15 increases; anxiety-like behavior elicited by adrenaline or restraint stress is eliminated in GFRAL-deficient mice, identifying GDF15-GFRAL as a link between lipolysis and anxiety behavior.","method":"ATGL knockout, β-adrenergic receptor knockout, GFRAL knockout mice, restraint stress model, GDF15 measurement in adipose tissue and plasma, anxiety behavioral assays","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic loss-of-function models with defined behavioral readout and tissue-specific origin of GDF15 identified","pmids":["40234625"],"is_preprint":false},{"year":2022,"finding":"GDF15 promotes liver fibrosis amelioration by reprogramming macrophage metabolism to an oxidative phosphorylation-dependent anti-inflammatory state; adoptive transfer of GDF15-preprogrammed macrophages to fibrotic mice attenuates inflammation and fibrosis.","method":"Gdf15 knockout mice, AAV8-mediated GDF15 overexpression, recombinant GDF15 treatment, adoptive macrophage transfer, metabolic pathway analysis in macrophages","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout, overexpression, and adoptive transfer with defined metabolic mechanism, single lab","pmids":["37499753"],"is_preprint":false},{"year":2024,"finding":"In sepsis-induced cardiomyopathy, GDF15 activates the ALK5-SMAD2/3 pathway, which inhibits SOCS1 expression, thereby activating the JAK2/STAT3 pathway, promoting GPX4 transcription and inhibiting ferroptosis in cardiomyocytes.","method":"Transcriptomic analysis, ALK5-SMAD2/3 signaling pathway assay, SOCS1 expression, JAK2/STAT3 and GPX4 measurements, mouse SIC model with GDF15 antagonism","journal":"European journal of pharmacology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway analysis based largely on expression data with limited direct mechanistic validation","pmids":["39147013"],"is_preprint":false},{"year":2024,"finding":"GDF15 blockade prevents cachexia and slows the progression of heart failure in a mouse model where PPP1R15A deficiency leads to increased cardiac Gdf15 expression and elevated circulating GDF15, indicating that cardiac stress drives a GDF15-dependent pathway promoting weight loss and worsening cardiac function.","method":"GDF15-blocking antibody treatment, PPP1R15A knockout bone marrow reconstitution mouse model, cardiac function assessment, Gdf15 expression analysis","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic model with pharmacological blockade demonstrating pathway requirement, single lab","pmids":["39312445"],"is_preprint":false},{"year":2018,"finding":"GDF15 in colorectal cancer cells promotes EMT and metastasis via TGFβR/Smad2/Smad3 pathway activation. GDF15 silencing by shRNA suppresses GDF15-induced cell invasion and migration in LoVo cells.","method":"GDF15 overexpression and shRNA knockdown, western blotting for EMT markers (N-cadherin, vimentin, Twist1, E-cadherin), cell invasion/migration assays","journal":"Artificial cells, nanomedicine, and biotechnology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell line; TGF-β receptor-mediated mechanism may be confounded by contamination issues","pmids":["29771147"],"is_preprint":false},{"year":2018,"finding":"C-reactive protein (CRP) stimulates GDF15 expression in endothelial cells through p53; CRP treatment of endothelial cells recruits p53 to binding sites in the GDF15 promoter, inducing GDF15 transcription.","method":"CRP treatment of human aortic endothelial cells, dual-luciferase reporter assay, chromatin immunoprecipitation (p53 binding to GDF15 promoter), CRP plasmid transfection","journal":"Mediators of inflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus luciferase reporter assay confirming direct p53 binding to GDF15 promoter, single lab","pmids":["29967567"],"is_preprint":false},{"year":2022,"finding":"GDF15 in cancer-associated fibroblasts binds GFRAL on melanoma cells, promoting RET phosphorylation, triggering downstream signaling that induces tumor cell stemness and secretion of CCL18 and TGF-β, leading to M2 macrophage polarization and immunosuppressive microenvironment.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter assay, recombinant protein rescue experiments, CRISPR knockout mice, Cre-loxP system mice, cell co-culture","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in a single lab including Co-IP and genetic models","pmids":["40555562"],"is_preprint":false},{"year":2021,"finding":"Single nuclei RNA sequencing identified a single population of GFRAL and RET co-expressing excitatory neurons in the area postrema as the primary direct cellular target of GDF15 in the hindbrain; GDF15 treatment induced cell-type-specific transcriptomic changes in these neurons and secondary changes in other neuronal and glial subtypes of the AP/NTS.","method":"Single nuclei RNA sequencing of AP and NTS micropunches from GDF15-treated vs. saline-treated rats","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — snRNAseq of ~35,000 nuclei providing cell-type-specific resolution of GDF15's direct targets, single lab","pmids":["34942400"],"is_preprint":false}],"current_model":"GDF15 is a stress-induced, furin-cleaved, disulfide-linked dimeric cytokine secreted by diverse cell types that signals primarily through a GFRAL-RET heterodimeric receptor complex exclusively expressed in area postrema and nucleus tractus solitarius neurons of the hindbrain, activating a neural circuit that reduces food intake, triggers aversive/nausea-like responses, activates the HPA axis via GFRAL, and — through a GFRAL-β-adrenergic axis — maintains energy expenditure in skeletal muscle; peripherally, GDF15 promotes adipose lipolysis via a sympathetic axis downstream of GFRAL and modulates macrophage metabolism and immune tolerance (including via a CD48 receptor on T cells in the immune microenvironment), while its transcription is regulated by p53, PPARγ, and the integrated stress response/AMPK pathway, and its maturation requires ARRB1-mediated trafficking to the Golgi."},"narrative":{"mechanistic_narrative":"GDF15 is a stress-induced, secreted dimeric cytokine that signals through a hindbrain receptor system to regulate feeding, energy balance, and stress responses [PMID:28846097, PMID:28846098, PMID:28846099, PMID:28953886]. It is synthesized as a 62-kDa precursor that is furin-cleaved and secreted as a 25-kDa disulfide-linked dimer [PMID:9886240], with maturation depending on β-arrestin1 (ARRB1)-mediated trafficking of pro-GDF15 to the Golgi [PMID:31857195]. Its canonical signaling axis requires the high-affinity receptor GFRAL, expressed exclusively in area postrema and nucleus tractus solitarius neurons that co-express the co-receptor RET, where GDF15 drives RET phosphorylation and activates a circuit reaching the parabrachial nucleus and central amygdala to suppress food intake and induce aversive responses [PMID:28846097, PMID:28846098, PMID:28846099, PMID:28953886, PMID:40555562, PMID:34942400]. Through GFRAL this axis also activates the HPA stress axis [PMID:34187898], counteracts adaptive thermogenesis via a β-adrenergic pathway that sustains fatty acid oxidation in skeletal muscle [PMID:37380764], and drives an adipose sympathetic-lipolytic program linking lipolysis to anxiety-like behavior [PMID:32661391, PMID:40234625]. The GDF15-GFRAL axis is the obligate mediator of metformin- and ketogenic-diet-induced weight loss, with GDF15 induced in kidney, intestine, and liver and its transcription controlled by the integrated stress response, AMPK, p53, and PPAR pathways [PMID:31875646, PMID:37060902, PMID:38056430, PMID:30639358, PMID:33337559, PMID:29967567]. GDF15 expression is also tuned post-transcriptionally by the CNOT6L deadenylase [PMID:35385705]. Beyond the CNS axis, GDF15 reprograms macrophage metabolism toward an anti-inflammatory oxidative state and stabilizes Treg FOXP3 by engaging CD48 on T cells, contributing to immune tolerance [PMID:37499753, PMID:34489334]. Reported GFRAL-independent actions in peripheral fibroblasts and hepatocytes engage the ALK5/SMAD pathway [PMID:35993367, PMID:38176644].","teleology":[{"year":1999,"claim":"Establishing how GDF15 becomes a secreted signal: it is produced as an intracellular precursor requiring proteolytic processing and dimerization before release.","evidence":"Biochemical characterization of precursor cleavage and secretion","pmids":["9886240"],"confidence":"Medium","gaps":["Did not identify the trafficking machinery required for maturation","No receptor or downstream signaling defined"]},{"year":1997,"claim":"First demonstration that GDF15 has direct biological activity, inhibiting hematopoietic progenitor proliferation.","evidence":"In vitro proliferation assay with hematopoietic progenitors","pmids":["9375789"],"confidence":"Low","gaps":["Single functional assay with no mechanistic detail","No receptor identified"]},{"year":2017,"claim":"Resolved the central question of how GDF15 signals: GFRAL is its high-affinity receptor, acting with RET co-receptor in restricted hindbrain neurons to mediate appetite and body weight suppression.","evidence":"Receptor binding, RET co-receptor identification, GFRAL knockout mice, in vivo pharmacology in mice and primates; replicated across four labs","pmids":["28846097","28846098","28846099","28953886"],"confidence":"High","gaps":["Did not resolve peripheral GFRAL-independent actions","Structural basis of the GDF15-GFRAL-RET ternary complex not defined here"]},{"year":2017,"claim":"Mapped GFRAL signaling to a defined neural circuit and demonstrated its requirement for chemotherapy-induced anorexia, framing GDF15 as an 'emergency' stress-feeding regulator.","evidence":"Neuronal activation mapping, GFRAL knockout mice, chemotherapy-induced anorexia model; crystal structure and gastric emptying assays","pmids":["28953886","29046435"],"confidence":"High","gaps":["Cell-type resolution of direct targets not yet defined","Downstream effector neurons of PBN/CeA circuit incompletely mapped"]},{"year":2019,"claim":"Established the trafficking step needed for maturation: ARRB1 binds pro-GDF15 and routes it to the Golgi, linking maturation defects to steatohepatitis.","evidence":"Co-IP, Arrb1 knockout mice, pro-GDF15 rescue experiments","pmids":["31857195"],"confidence":"Medium","gaps":["Single Co-IP for the ARRB1-GDF15 interaction","Whether ARRB1 acts on all GDF15-producing tissues unknown"]},{"year":2019,"claim":"Connected GDF15 to clinical pharmacology by showing the GDF15-GFRAL axis is required for metformin-induced weight loss, and tied GDF15 induction to the integrated stress response.","evidence":"Human RCTs, GDF15 and GFRAL knockout mice, GFRAL-antagonist antibody, dietary models, conditioned taste aversion","pmids":["31875646","30639358"],"confidence":"High","gaps":["Tissue source of metformin-induced GDF15 not fully resolved at this stage","Molecular link between ISR sensors and Gdf15 transcription not detailed"]},{"year":2021,"claim":"Extended GFRAL signaling beyond feeding to endocrine stress, showing GDF15 activates the HPA axis and is required for stress-toxin-induced corticosterone responses.","evidence":"GDF15 administration with GFRAL-blocking antibody, Gdf15 knockout mice, multiple stress models, corticosterone readout","pmids":["34187898"],"confidence":"High","gaps":["Circuit linking GFRAL neurons to HPA axis not mapped","Physiological stressors driving endogenous response incompletely defined"]},{"year":2020,"claim":"Defined a peripheral effector branch: GFRAL activation drives a sympathetic-lipolytic axis in adipose tissue, and a GFRAL antagonist blocks GDF15-driven RET recruitment.","evidence":"Antagonistic antibody, chemical sympathectomy, ATGL knockout mice, adipose gene expression, tumor-bearing models","pmids":["32661391"],"confidence":"High","gaps":["How a hindbrain receptor produces sympathetic output to adipose not fully mapped"]},{"year":2023,"claim":"Showed GDF15 maintains energy expenditure against caloric-restriction-induced adaptive thermogenesis via a GFRAL-β-adrenergic axis acting on skeletal muscle.","evidence":"Recombinant GDF15, caloric restriction, fatty acid oxidation and calcium futile cycling assays in muscle","pmids":["37380764"],"confidence":"High","gaps":["Identity of intermediary neurons relaying GFRAL signal to muscle unclear"]},{"year":2023,"claim":"Refined the source of metformin-induced GDF15 to the kidney and confirmed dual-site (kidney GDF15, area postrema GFRAL) requirement for drug action.","evidence":"Tissue-specific AAV knockdown of GDF15 in kidney and GFRAL in area postrema in rats","pmids":["37060902"],"confidence":"High","gaps":["Mechanism of metformin-driven renal GDF15 induction not detailed"]},{"year":2023,"claim":"Identified hepatic PPARγ as a direct transcriptional driver of Gdf15 mediating ketogenic-diet weight loss through GFRAL.","evidence":"PPARγ ChIP, hepatocyte-specific Gdf15 knockdown, GDF15/GFRAL/hepatic PPARγ knockouts, recombinant rescue","pmids":["38056430"],"confidence":"High","gaps":["Interplay between PPARγ and other Gdf15 regulators (p53, AMPK) not integrated"]},{"year":2021,"claim":"Defined transcriptional and feedback control of GDF15 expression through p53, PPARβ/δ-AMPK, and energetic stress sensing.","evidence":"ChIP/luciferase for p53 (CRP-induced), PPARβ/δ epistasis, AMPKβ1 knockout mice with direct activators","pmids":["29967567","34380027","33337559"],"confidence":"Medium","gaps":["Relative contribution of each pathway in vivo unclear","Direct AMPK-to-Gdf15 transcriptional link not fully defined"]},{"year":2022,"claim":"Revealed a positive feedback loop in which GDF15 is needed for full AMPK activation by metformin in liver and muscle independently of GFRAL, and uncovered CNOT6L as a post-transcriptional regulator.","evidence":"Gdf15 knockout/siRNA, AMPK assays, metformin; CNOT6L inhibition with mRNA stability assay","pmids":["36435271","35385705"],"confidence":"Medium","gaps":["GFRAL-independent peripheral receptor for the AMPK feedback not identified","Direct CNOT6L target site on Gdf15 mRNA not mapped"]},{"year":2021,"claim":"Established GDF15 as an immunomodulator, stabilizing Treg FOXP3 by engaging CD48 on T cells and downregulating STUB1.","evidence":"Co-IP, mass spectrometry, ChIP, Gdf15 knockout, flow cytometry, RNA-seq in HCC","pmids":["34489334"],"confidence":"Medium","gaps":["CD48 as a functional GDF15 receptor needs reciprocal validation","Relationship to canonical GFRAL signaling unclear"]},{"year":2022,"claim":"Demonstrated GDF15 reprograms macrophages toward an anti-inflammatory oxidative-phosphorylation state, attenuating liver fibrosis.","evidence":"Gdf15 knockout, AAV8 overexpression, recombinant GDF15, adoptive macrophage transfer, metabolic profiling","pmids":["37499753"],"confidence":"Medium","gaps":["Receptor mediating macrophage effect not identified","Single-disease context"]},{"year":2023,"claim":"Linked peripheral lipolysis to behavior, showing adipose-macrophage-derived GDF15 mediates β-adrenergic-induced anxiety via GFRAL.","evidence":"ATGL, β-adrenergic receptor, and GFRAL knockout mice, restraint stress, anxiety assays, tissue GDF15 measurement","pmids":["40234625"],"confidence":"High","gaps":["Circuit translating GFRAL activation into anxiety behavior not mapped"]},{"year":2021,"claim":"Resolved cell-type resolution of GDF15's central target as a single GFRAL/RET co-expressing excitatory AP neuron population.","evidence":"Single nuclei RNA sequencing of AP/NTS from GDF15-treated rats","pmids":["34942400"],"confidence":"Medium","gaps":["Functional dissection of transcriptomic changes not performed","Secondary glial/neuronal effects not mechanistically resolved"]},{"year":2022,"claim":"Distinguished pharmacological from physiological GDF15 and from GLP-1 agonism: GDF15 induces malaise without altering feeding motivation, and physiological exercise-induced GDF15 does not affect appetite.","evidence":"Operant paradigms, CCK potentiation, pica/aversion tests, AgRP fibre photometry, human exercise studies","pmids":["33589633","35129264"],"confidence":"Medium","gaps":["Why physiological and pharmacological GDF15 differ despite similar levels unresolved","Single lab group for the mechanistic comparison"]},{"year":2024,"claim":"Characterized GFRAL-independent peripheral actions through ALK5/SMAD signaling in fibroblasts and hepatocytes, with context-dependent pro- and anti-fibrotic outcomes.","evidence":"ALK5 inhibitor and SMAD3 inhibition, recombinant GDF15, Gdf15 knockout and bleomycin/SIC/PPP1R15A disease models","pmids":["35993367","38176644","39147013","39312445"],"confidence":"Medium","gaps":["Direct ALK5/TGFβR binding contested due to possible TGF-β contamination","Reconciliation with GFRAL-restricted canonical model not achieved"]},{"year":null,"claim":"It remains unresolved how GDF15 exerts its reported GFRAL-independent peripheral effects mechanistically, including the identity of any peripheral receptor and validation of CD48 and ALK5/TGFβR engagement.","evidence":"","pmids":[],"confidence":"Low","gaps":["No validated GFRAL-independent receptor","TGFβR/ALK5 claims confounded by contamination concerns","CD48 interaction lacks reciprocal validation"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,3,37]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,9,12]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,5]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3,12]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,12,14,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[17,32]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[6,9,23]}],"complexes":[],"partners":["GFRAL","RET","ARRB1","CD48"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99988","full_name":"Growth/differentiation factor 15","aliases":["Macrophage inhibitory cytokine 1","MIC-1","NSAID-activated gene 1 protein","NAG-1","NSAID-regulated gene 1 protein","NRG-1","Placental TGF-beta","Placental bone morphogenetic protein","Prostate differentiation factor"],"length_aa":308,"mass_kda":34.1,"function":"Hormone produced in response to various stresses to confer information about those stresses to the brain, and trigger an aversive response, characterized by nausea, vomiting, and/or loss of appetite (PubMed:23468844, PubMed:24971956, PubMed:28846097, PubMed:28846098, PubMed:28846099, PubMed:28953886, PubMed:29046435, PubMed:30639358, PubMed:31875646, PubMed:33589633, PubMed:38092039). The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future (PubMed:30639358, PubMed:33589633, PubMed:38092039). Acts by binding to its receptor, GFRAL, activating GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem (PubMed:28846097, PubMed:28846098, PubMed:28846099, PubMed:28953886, PubMed:31535977). It then triggers the activation of neurons localized within the parabrachial nucleus and central amygdala, which constitutes part of the 'emergency circuit' that shapes responses to stressful conditions (PubMed:28953886). The GDF15-GFRAL signal induces expression of genes involved in metabolism, such as lipid metabolism in adipose tissues (PubMed:31402172). Required for avoidance behavior in response to food allergens: induced downstream of mast cell activation to promote aversion and minimize harmful effects of exposure to noxious substances (By similarity). In addition to suppress appetite, also promotes weight loss by enhancing energy expenditure in muscle: acts by increasing calcium futile cycling in muscle (By similarity). Contributes to the effect of metformin, an anti-diabetic drug, on appetite reduction and weight loss: produced in the kidney in response to metformin treatment, thereby activating the GDF15-GFRAL response, leading to reduced appetite and weight (PubMed:31875646, PubMed:37060902). The contribution of GDF15 to weight loss following metformin treatment is however limited and subject to discussion (PubMed:36001956). Produced in response to anticancer drugs, such as camptothecin or cisplatin, promoting nausea, vomiting and contributing to malnutrition (By similarity). Overproduced in many cancers, promoting anorexia in cancer (cachexia) (PubMed:32661391). Responsible for the risk of nausea and vomiting during pregnancy: high levels of GDF15 during pregnancy, mostly originating from the fetus, are associated with increased nausea and vomiting (PubMed:38092039). Maternal sensitivity to nausea is probably determined by pre-pregnancy exposure to GDF15, women with naturally high level of GDF15 being less susceptible to nausea than women with low levels of GDF15 before pregnancy (PubMed:38092039). Promotes metabolic adaptation in response to systemic inflammation caused by bacterial and viral infections in order to promote tissue tolerance and prevent tissue damage (PubMed:31402172). Required for tissue tolerance in response to myocardial infarction by acting as an inhibitor of leukocyte integring activation, thereby protecting against cardiac rupture (By similarity). Inhibits growth hormone signaling on hepatocytes (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q99988/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GDF15","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GDF15","total_profiled":1310},"omim":[{"mim_id":"621503","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 39; LRRC39","url":"https://www.omim.org/entry/621503"},{"mim_id":"621298","title":"GLYCINE-RICH EXTRACELLULAR PROTEIN 1; GREP1","url":"https://www.omim.org/entry/621298"},{"mim_id":"620730","title":"HYPEREMESIS GRAVIDARUM, SUSCEPTIBILITY TO; HG","url":"https://www.omim.org/entry/620730"},{"mim_id":"619538","title":"CEREBRAL CAVERNOUS MALFORMATIONS 4; CCM4","url":"https://www.omim.org/entry/619538"},{"mim_id":"617837","title":"GDNF FAMILY RECEPTOR ALPHA-LIKE PROTEIN; GFRAL","url":"https://www.omim.org/entry/617837"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Golgi apparatus","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"kidney","ntpm":328.4}],"url":"https://www.proteinatlas.org/search/GDF15"},"hgnc":{"alias_symbol":["PLAB","MIC-1","PDF","MIC1","NAG-1","PTGFB"],"prev_symbol":[]},"alphafold":{"accession":"Q99988","domains":[{"cath_id":"2.10.90.10","chopping":"213-308","consensus_level":"high","plddt":94.7713,"start":213,"end":308},{"cath_id":"2.40.30","chopping":"86-168_176-187","consensus_level":"high","plddt":75.5677,"start":86,"end":187}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99988","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99988-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99988-F1-predicted_aligned_error_v6.png","plddt_mean":75.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GDF15","jax_strain_url":"https://www.jax.org/strain/search?query=GDF15"},"sequence":{"accession":"Q99988","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99988.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99988/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99988"}},"corpus_meta":[{"pmid":"28846097","id":"PMC_28846097","title":"GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28846097","citation_count":626,"is_preprint":false},{"pmid":"28846098","id":"PMC_28846098","title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28846098","citation_count":552,"is_preprint":false},{"pmid":"28846099","id":"PMC_28846099","title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28846099","citation_count":543,"is_preprint":false},{"pmid":"28953886","id":"PMC_28953886","title":"Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28953886","citation_count":508,"is_preprint":false},{"pmid":"31875646","id":"PMC_31875646","title":"GDF15 mediates the effects of metformin on body weight and energy balance.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31875646","citation_count":447,"is_preprint":false},{"pmid":"34381196","id":"PMC_34381196","title":"GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.","date":"2021","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34381196","citation_count":409,"is_preprint":false},{"pmid":"32508832","id":"PMC_32508832","title":"Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32508832","citation_count":404,"is_preprint":false},{"pmid":"30639358","id":"PMC_30639358","title":"GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans.","date":"2019","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30639358","citation_count":403,"is_preprint":false},{"pmid":"30184485","id":"PMC_30184485","title":"The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.","date":"2018","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30184485","citation_count":336,"is_preprint":false},{"pmid":"32661391","id":"PMC_32661391","title":"Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice.","date":"2020","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32661391","citation_count":258,"is_preprint":false},{"pmid":"9886240","id":"PMC_9886240","title":"MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9886240","citation_count":235,"is_preprint":false},{"pmid":"9375789","id":"PMC_9375789","title":"PLAB, a novel placental bone morphogenetic protein.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9375789","citation_count":218,"is_preprint":false},{"pmid":"32310257","id":"PMC_32310257","title":"GDF15: A Hormone Conveying Somatic Distress to the Brain.","date":"2020","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32310257","citation_count":209,"is_preprint":false},{"pmid":"24531647","id":"PMC_24531647","title":"NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism.","date":"2014","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/24531647","citation_count":209,"is_preprint":false},{"pmid":"29046435","id":"PMC_29046435","title":"Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys.","date":"2017","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29046435","citation_count":196,"is_preprint":false},{"pmid":"37380764","id":"PMC_37380764","title":"GDF15 promotes weight loss by enhancing energy expenditure in muscle.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37380764","citation_count":192,"is_preprint":false},{"pmid":"33228454","id":"PMC_33228454","title":"The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?","date":"2020","source":"Annual review of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33228454","citation_count":179,"is_preprint":false},{"pmid":"29636108","id":"PMC_29636108","title":"GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29636108","citation_count":172,"is_preprint":false},{"pmid":"30790643","id":"PMC_30790643","title":"Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases.","date":"2019","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30790643","citation_count":153,"is_preprint":false},{"pmid":"30542297","id":"PMC_30542297","title":"GDF15 and Growth Control.","date":"2018","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30542297","citation_count":147,"is_preprint":false},{"pmid":"35051643","id":"PMC_35051643","title":"GDF15, an emerging key player in human aging.","date":"2022","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35051643","citation_count":141,"is_preprint":false},{"pmid":"23220538","id":"PMC_23220538","title":"The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer.","date":"2012","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23220538","citation_count":139,"is_preprint":false},{"pmid":"34836750","id":"PMC_34836750","title":"Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia.","date":"2021","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/34836750","citation_count":138,"is_preprint":false},{"pmid":"26497212","id":"PMC_26497212","title":"GDF15 promotes EMT and metastasis in colorectal cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26497212","citation_count":138,"is_preprint":false},{"pmid":"34489334","id":"PMC_34489334","title":"GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34489334","citation_count":137,"is_preprint":false},{"pmid":"33172749","id":"PMC_33172749","title":"Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets.","date":"2020","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/33172749","citation_count":136,"is_preprint":false},{"pmid":"34445593","id":"PMC_34445593","title":"GDF15 and Cardiac Cells: Current Concepts and New Insights.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34445593","citation_count":118,"is_preprint":false},{"pmid":"32936319","id":"PMC_32936319","title":"GDF15, an update of the physiological and pathological roles it plays: a review.","date":"2020","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32936319","citation_count":113,"is_preprint":false},{"pmid":"33589633","id":"PMC_33589633","title":"Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33589633","citation_count":109,"is_preprint":false},{"pmid":"35504134","id":"PMC_35504134","title":"Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/35504134","citation_count":107,"is_preprint":false},{"pmid":"32929274","id":"PMC_32929274","title":"A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma.","date":"2020","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32929274","citation_count":106,"is_preprint":false},{"pmid":"29866502","id":"PMC_29866502","title":"Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.","date":"2018","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/29866502","citation_count":102,"is_preprint":false},{"pmid":"34831213","id":"PMC_34831213","title":"The Role of GDF15 as a Myomitokine.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34831213","citation_count":100,"is_preprint":false},{"pmid":"21940482","id":"PMC_21940482","title":"Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease.","date":"2011","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/21940482","citation_count":98,"is_preprint":false},{"pmid":"34380027","id":"PMC_34380027","title":"GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34380027","citation_count":89,"is_preprint":false},{"pmid":"33421539","id":"PMC_33421539","title":"GDF15 as a biomarker of ageing.","date":"2021","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/33421539","citation_count":87,"is_preprint":false},{"pmid":"34187898","id":"PMC_34187898","title":"Activation of the hypothalamic-pituitary-adrenal axis by exogenous and endogenous GDF15.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34187898","citation_count":82,"is_preprint":false},{"pmid":"29161287","id":"PMC_29161287","title":"TGF-β contamination of purified recombinant GDF15.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29161287","citation_count":76,"is_preprint":false},{"pmid":"35058441","id":"PMC_35058441","title":"GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation.","date":"2022","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/35058441","citation_count":76,"is_preprint":false},{"pmid":"11205146","id":"PMC_11205146","title":"GDF-15/MIC-1 a novel member of the TGF-beta superfamily.","date":"2000","source":"Journal of neural transmission. Supplementum","url":"https://pubmed.ncbi.nlm.nih.gov/11205146","citation_count":71,"is_preprint":false},{"pmid":"32209255","id":"PMC_32209255","title":"GDF15 knockdown promotes erastin-induced ferroptosis by decreasing SLC7A11 expression.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32209255","citation_count":69,"is_preprint":false},{"pmid":"29129392","id":"PMC_29129392","title":"Targeting Obesity and Cachexia: Identification of the GFRAL Receptor-MIC-1/GDF15 Pathway.","date":"2017","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29129392","citation_count":67,"is_preprint":false},{"pmid":"37060902","id":"PMC_37060902","title":"Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight.","date":"2023","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37060902","citation_count":66,"is_preprint":false},{"pmid":"31857195","id":"PMC_31857195","title":"ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.","date":"2019","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/31857195","citation_count":64,"is_preprint":false},{"pmid":"33442410","id":"PMC_33442410","title":"GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33442410","citation_count":61,"is_preprint":false},{"pmid":"36367498","id":"PMC_36367498","title":"NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36367498","citation_count":60,"is_preprint":false},{"pmid":"12763036","id":"PMC_12763036","title":"Dysregulated expression of MIC-1/PDF in human prostate tumor cells.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12763036","citation_count":60,"is_preprint":false},{"pmid":"37499753","id":"PMC_37499753","title":"GDF15 Ameliorates Liver Fibrosis by Metabolic Reprogramming of Macrophages to Acquire Anti-Inflammatory Properties.","date":"2023","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37499753","citation_count":58,"is_preprint":false},{"pmid":"35993367","id":"PMC_35993367","title":"Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35993367","citation_count":56,"is_preprint":false},{"pmid":"15102773","id":"PMC_15102773","title":"Cloning and characterization of the gene encoding the major cell-associated phospholipase A of Legionella pneumophila, plaB, exhibiting hemolytic activity.","date":"2004","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15102773","citation_count":47,"is_preprint":false},{"pmid":"34849709","id":"PMC_34849709","title":"GDF15 in Appetite and Exercise: Essential Player or Coincidental Bystander?","date":"2022","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34849709","citation_count":46,"is_preprint":false},{"pmid":"32504264","id":"PMC_32504264","title":"Growth differentiation factor 15 (GDF15) in cancer cell metastasis: from the cells to the patients.","date":"2020","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/32504264","citation_count":46,"is_preprint":false},{"pmid":"35129264","id":"PMC_35129264","title":"Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms.","date":"2022","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35129264","citation_count":45,"is_preprint":false},{"pmid":"38056430","id":"PMC_38056430","title":"GDF15 is a major determinant of ketogenic diet-induced weight loss.","date":"2023","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38056430","citation_count":44,"is_preprint":false},{"pmid":"35385705","id":"PMC_35385705","title":"Deadenylase-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure.","date":"2022","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35385705","citation_count":43,"is_preprint":false},{"pmid":"36444166","id":"PMC_36444166","title":"Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.","date":"2022","source":"Journal of diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/36444166","citation_count":43,"is_preprint":false},{"pmid":"38810400","id":"PMC_38810400","title":"Overview of growth differentiation factor 15 (GDF15) in metabolic diseases.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/38810400","citation_count":42,"is_preprint":false},{"pmid":"36769245","id":"PMC_36769245","title":"GDF15 Promotes Cell Growth, Migration, and Invasion in Gastric Cancer by Inducing STAT3 Activation.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36769245","citation_count":42,"is_preprint":false},{"pmid":"29653105","id":"PMC_29653105","title":"CST3 and GDF15 ameliorate renal fibrosis by inhibiting fibroblast growth and activation.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29653105","citation_count":42,"is_preprint":false},{"pmid":"33337559","id":"PMC_33337559","title":"AMPK mediates energetic stress-induced liver GDF15.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33337559","citation_count":41,"is_preprint":false},{"pmid":"32416083","id":"PMC_32416083","title":"Senescent Fibroblast-Derived GDF15 Induces Skin Pigmentation.","date":"2020","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/32416083","citation_count":40,"is_preprint":false},{"pmid":"29967567","id":"PMC_29967567","title":"CRP Stimulates GDF15 Expression in Endothelial Cells through p53.","date":"2018","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29967567","citation_count":39,"is_preprint":false},{"pmid":"34294853","id":"PMC_34294853","title":"The anti-diabetic effects of NAG-1/GDF15 on HFD/STZ-induced mice.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34294853","citation_count":38,"is_preprint":false},{"pmid":"36151002","id":"PMC_36151002","title":"Knocking on GDF15's door for the treatment of type 2 diabetes mellitus.","date":"2022","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/36151002","citation_count":38,"is_preprint":false},{"pmid":"38176644","id":"PMC_38176644","title":"GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway.","date":"2024","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/38176644","citation_count":37,"is_preprint":false},{"pmid":"37093513","id":"PMC_37093513","title":"GDF15 as a key disease target and biomarker: linking chronic lung diseases and ageing.","date":"2023","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37093513","citation_count":37,"is_preprint":false},{"pmid":"36001956","id":"PMC_36001956","title":"The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36001956","citation_count":37,"is_preprint":false},{"pmid":"37433299","id":"PMC_37433299","title":"GDF15 enhances body weight and adiposity reduction in obese mice by leveraging the leptin pathway.","date":"2023","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37433299","citation_count":36,"is_preprint":false},{"pmid":"29724997","id":"PMC_29724997","title":"Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29724997","citation_count":36,"is_preprint":false},{"pmid":"37129758","id":"PMC_37129758","title":"Growth differentiation factor 15 (GDF-15) in endocrinology.","date":"2023","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/37129758","citation_count":35,"is_preprint":false},{"pmid":"36435271","id":"PMC_36435271","title":"A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/36435271","citation_count":35,"is_preprint":false},{"pmid":"33188737","id":"PMC_33188737","title":"Mitochondrial stress and GDF15 in the pathophysiology of sepsis.","date":"2020","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/33188737","citation_count":34,"is_preprint":false},{"pmid":"35148379","id":"PMC_35148379","title":"NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice.","date":"2022","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35148379","citation_count":33,"is_preprint":false},{"pmid":"32304740","id":"PMC_32304740","title":"Functional roles of GDF15 in modulating microenvironment to promote carcinogenesis.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32304740","citation_count":33,"is_preprint":false},{"pmid":"39472228","id":"PMC_39472228","title":"GDF15 is still a mystery hormone.","date":"2024","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/39472228","citation_count":32,"is_preprint":false},{"pmid":"35202387","id":"PMC_35202387","title":"Camptothecin effectively treats obesity in mice through GDF15 induction.","date":"2022","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/35202387","citation_count":32,"is_preprint":false},{"pmid":"34566964","id":"PMC_34566964","title":"The Clinical Value of GDF15 and Its Prospective Mechanism in Sepsis.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34566964","citation_count":32,"is_preprint":false},{"pmid":"30947652","id":"PMC_30947652","title":"GDF-15: A Multifunctional Modulator and Potential Therapeutic Target in Cancer.","date":"2019","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/30947652","citation_count":31,"is_preprint":false},{"pmid":"39312445","id":"PMC_39312445","title":"GDF15 antagonism limits severe heart failure and prevents cardiac cachexia.","date":"2024","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/39312445","citation_count":30,"is_preprint":false},{"pmid":"38310105","id":"PMC_38310105","title":"Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38310105","citation_count":30,"is_preprint":false},{"pmid":"31172564","id":"PMC_31172564","title":"GDF15 induced apoptosis and cytotoxicity in A549 cells depends on TGFBR2 expression.","date":"2019","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/31172564","citation_count":30,"is_preprint":false},{"pmid":"20153694","id":"PMC_20153694","title":"Phospholipase PlaB is a new virulence factor of Legionella pneumophila.","date":"2010","source":"International journal of medical microbiology : IJMM","url":"https://pubmed.ncbi.nlm.nih.gov/20153694","citation_count":28,"is_preprint":false},{"pmid":"39000420","id":"PMC_39000420","title":"Macrophages as a Source and Target of GDF-15.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39000420","citation_count":27,"is_preprint":false},{"pmid":"39147013","id":"PMC_39147013","title":"GDF15 attenuates sepsis-induced myocardial dysfunction by inhibiting cardiomyocytes ferroptosis via the SOCS1/GPX4 signaling pathway.","date":"2024","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39147013","citation_count":27,"is_preprint":false},{"pmid":"19640837","id":"PMC_19640837","title":"Phospholipase PlaB of Legionella pneumophila represents a novel lipase family: protein residues essential for lipolytic activity, substrate specificity, and hemolysis.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19640837","citation_count":26,"is_preprint":false},{"pmid":"29771147","id":"PMC_29771147","title":"GDF15 promotes epithelial-to-mesenchymal transition in colorectal [corrected].","date":"2018","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29771147","citation_count":25,"is_preprint":false},{"pmid":"36427806","id":"PMC_36427806","title":"The GDF15-GFRAL axis mediates chemotherapy-induced fatigue in mice.","date":"2022","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36427806","citation_count":24,"is_preprint":false},{"pmid":"35138971","id":"PMC_35138971","title":"GDF15: a potential therapeutic target for type 1 diabetes.","date":"2022","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/35138971","citation_count":23,"is_preprint":false},{"pmid":"38892145","id":"PMC_38892145","title":"GDF15, an Emerging Player in Renal Physiology and Pathophysiology.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38892145","citation_count":23,"is_preprint":false},{"pmid":"36465107","id":"PMC_36465107","title":"Hepatocyte-derived GDF15 suppresses feeding and improves insulin sensitivity in obese mice.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36465107","citation_count":22,"is_preprint":false},{"pmid":"40234625","id":"PMC_40234625","title":"GDF15 links adipose tissue lipolysis with anxiety.","date":"2025","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40234625","citation_count":21,"is_preprint":false},{"pmid":"40555562","id":"PMC_40555562","title":"Ectopic expression of GDF15 in cancer-associated fibroblasts enhances melanoma immunosuppression via the GFRAL/RET cascade.","date":"2025","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40555562","citation_count":21,"is_preprint":false},{"pmid":"39643709","id":"PMC_39643709","title":"GDF15/MIC-1: a stress-induced immunosuppressive factor which promotes the aging process.","date":"2024","source":"Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/39643709","citation_count":20,"is_preprint":false},{"pmid":"34942400","id":"PMC_34942400","title":"Single nuclei RNA sequencing of the rat AP and NTS following GDF15 treatment.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34942400","citation_count":20,"is_preprint":false},{"pmid":"36205439","id":"PMC_36205439","title":"Growth and differentiation factor 15 (GDF15) levels predict adverse respiratory outcomes in premature neonates.","date":"2022","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/36205439","citation_count":20,"is_preprint":false},{"pmid":"31545486","id":"PMC_31545486","title":"GDF15 promotes osteosarcoma cell migration and invasion by regulating the TGF‑β signaling pathway.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/31545486","citation_count":20,"is_preprint":false},{"pmid":"30382947","id":"PMC_30382947","title":"Targeting the divergent TGFβ superfamily cytokine MIC-1/GDF15 for therapy of anorexia/cachexia syndromes.","date":"2018","source":"Current opinion in supportive and palliative care","url":"https://pubmed.ncbi.nlm.nih.gov/30382947","citation_count":19,"is_preprint":false},{"pmid":"31474335","id":"PMC_31474335","title":"Competitive inhibition by NAG-1/GDF-15 NLS peptide enhances its anti-cancer activity.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31474335","citation_count":19,"is_preprint":false},{"pmid":"37584611","id":"PMC_37584611","title":"Cross-species comparison of pregnancy-induced GDF15.","date":"2023","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37584611","citation_count":18,"is_preprint":false},{"pmid":"25867265","id":"PMC_25867265","title":"MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma.","date":"2015","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25867265","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46524,"output_tokens":9116,"usd":0.138156,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19637,"output_tokens":5520,"usd":0.118093,"stage2_stop_reason":"end_turn"},"total_usd":0.256249,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"MIC-1/GDF15 is synthesized as a 62-kDa intracellular precursor protein that is cleaved by a furin-like protease and secreted as a 25-kDa disulfide-linked dimeric protein.\",\n      \"method\": \"Protein expression analysis, biochemical characterization of cleavage and dimerization\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical characterization in a single lab with multiple orthogonal methods (size analysis, protease identification, secretion assay)\",\n      \"pmids\": [\"9886240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"GDF15/PLAB inhibits the proliferation of primitive hematopoietic progenitors, demonstrating a direct biological activity.\",\n      \"method\": \"In vitro proliferation assay with hematopoietic progenitors\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single functional assay, limited mechanistic detail in abstract\",\n      \"pmids\": [\"9375789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GDNF family receptor α-like (GFRAL) is the high-affinity receptor for GDF15; GDF15 binds GFRAL with high affinity and requires GFRAL to elicit intracellular signaling through the co-receptor RET. GFRAL expression is restricted to neurons of the area postrema and nucleus of the solitary tract in the hindbrain. Genetic deletion of GFRAL abolishes GDF15-induced reductions in food intake and body weight in mice.\",\n      \"method\": \"Receptor binding assays, co-receptor identification (RET), GFRAL knockout mice, in vivo pharmacology in mice and nonhuman primates\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — independently replicated by four labs simultaneously (PMIDs 28846097, 28846098, 28846099, 28953886) using binding assays, knockout models, and in vivo pharmacology\",\n      \"pmids\": [\"28846097\", \"28846098\", \"28846099\", \"28953886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GDF15 activates neurons in the area postrema and nucleus tractus solitarius via GFRAL, which then triggers activation of neurons in the parabrachial nucleus and central amygdala as part of an 'emergency circuit' regulating feeding responses under stress. GFRAL knockout mice are resistant to chemotherapy-induced anorexia and body weight loss.\",\n      \"method\": \"Neuronal activation mapping, GFRAL knockout mice, chemotherapy-induced anorexia model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with defined phenotypic readout, neural circuit mapping, replicated across multiple labs\",\n      \"pmids\": [\"28953886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GDF15 delays gastric emptying and activates area postrema neurons, consistent with a gut-brain axis role in regulating energy intake. Crystal structure analysis of GDF15 informed structure-guided design of Fc fusion proteins with extended half-life.\",\n      \"method\": \"Gastric emptying assay, area postrema neuron activation imaging, GDF15 crystal structure analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — crystal structure combined with functional in vivo assays in a single lab\",\n      \"pmids\": [\"29046435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Metformin increases circulating GDF15 levels, with GDF15 expression increasing predominantly in the distal intestine and kidney. Metformin's effects on body weight and energy balance are absent in GDF15 knockout mice and GFRAL knockout mice, and are reversed by a GFRAL-antagonist antibody, demonstrating that the GDF15-GFRAL axis is required for metformin-induced weight loss.\",\n      \"method\": \"Randomized controlled trials (human), GDF15 and GFRAL knockout mice, GFRAL-antagonist antibody treatment, tissue-specific expression analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including human RCTs, genetic knockout models, and pharmacological antagonism in a single comprehensive study\",\n      \"pmids\": [\"31875646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF15 expression is regulated by the integrated stress response and is induced in selected tissues by sustained high-fat feeding or dietary amino acid imbalance. Pharmacological GDF15 administration triggers conditioned taste aversion in mice, indicating an aversive component to its anorectic action.\",\n      \"method\": \"Mouse dietary models, conditioned taste aversion assay, tissue expression analysis\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple dietary models and behavioral assay in a single lab\",\n      \"pmids\": [\"30639358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A GFRAL-antagonist monoclonal antibody (3P10) inhibits RET signaling by preventing the GDF15-driven interaction of RET with GFRAL on the cell surface. GDF15-GFRAL-RET pathway activation induces lipid metabolism gene expression in adipose tissue; peripheral chemical sympathectomy and loss of adipose triglyceride lipase protect mice from GDF15-induced weight loss, revealing a peripheral sympathetic-lipolytic axis downstream of GFRAL.\",\n      \"method\": \"Antagonistic antibody treatment, chemical sympathectomy, adipose triglyceride lipase knockout mice, gene expression analysis in adipose tissue, tumor-bearing mouse models\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genetic and pharmacological approaches with defined molecular mechanism in a single rigorous study\",\n      \"pmids\": [\"32661391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Transgenic overexpression of human NAG-1/GDF15 in mice increases thermogenic gene expression (UCP1, PGC1α, and others) in brown adipose tissue and lipolytic gene expression (Adrb3, ATGL, HSL) in white and brown adipose tissue, resulting in increased energy expenditure and resistance to diet-induced obesity without reducing food intake.\",\n      \"method\": \"Transgenic mouse overexpression model, high-fat diet challenge, gene expression analysis (thermogenic and lipolytic genes), xenograft model\",\n      \"journal\": \"International journal of obesity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic overexpression and xenograft model with defined gene expression readouts in a single lab\",\n      \"pmids\": [\"24531647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF15 potently activates the hypothalamic-pituitary-adrenal (HPA) axis in mice and rats via GFRAL; a blocking antibody to GFRAL completely prevented the corticosterone response to GDF15 administration. In wild-type mice, endogenous GDF15 is required for HPA axis activation in response to genotoxic or endoplasmic reticulum toxins (which do not provoke cytokine responses), as shown by the absence of this response in Gdf15-/- mice.\",\n      \"method\": \"GDF15 administration with GFRAL-blocking antibody, Gdf15 knockout mice, corticosterone measurement, multiple stress models (LPS, genotoxic, ER toxins)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function and pharmacological blockade with multiple orthogonal stress models and defined endocrine readout\",\n      \"pmids\": [\"34187898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PPARβ/δ activation increases GDF15 levels via an AMPK-p53 pathway, and GDF15 in turn sustains AMPK activation; the metabolic effects of PPARβ/δ activation (glucose tolerance improvement, fatty acid oxidation, ER stress reduction, AMPK activation) are abrogated by GDF15 neutralizing antibody or in Gdf15-/- mice.\",\n      \"method\": \"GDF15 neutralizing antibody, Gdf15 knockout mice, pharmacological PPARβ/δ activation, AMPK activity assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological epistasis with defined pathway placement in a single lab\",\n      \"pmids\": [\"34380027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF15 combined with leptin causes greater weight and adiposity loss in obese mice than either treatment alone. GFRAL-expressing neurons in the hindbrain are extensively connected with leptin receptor (LepR)-expressing neurons; LepR knockdown in the NTS reduces GDF15-mediated AP neuronal activation, indicating that leptin signaling in the hindbrain potentiates GDF15's metabolic actions.\",\n      \"method\": \"Combined GDF15 and leptin infusion in obese mice, leptin receptor knockdown in NTS, hindbrain neuronal activation mapping, leptin-deficient ob/ob mice and competitive leptin antagonist\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple complementary genetic and pharmacological approaches with defined neural circuit readout in a single lab\",\n      \"pmids\": [\"37433299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GDF15 counteracts adaptive thermogenesis (compensatory reduction in energy expenditure during caloric restriction) by maintaining energy expenditure through a GFRAL-β-adrenergic-dependent signaling axis that increases fatty acid oxidation and calcium futile cycling in skeletal muscle of mice.\",\n      \"method\": \"Recombinant GDF15 treatment, caloric restriction models, β-adrenergic signaling analysis, fatty acid oxidation and calcium futile cycling assays in skeletal muscle\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal mechanistic assays (fatty acid oxidation, calcium cycling, β-adrenergic pathway) with defined GFRAL-dependent mechanism\",\n      \"pmids\": [\"37380764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Metformin increases plasma GDF15 levels by upregulating GDF15 synthesis specifically in the kidney. Kidney-specific knockdown of GDF15 expression, as well as area postrema-specific knockdown of GFRAL, negated the ability of metformin to lower food intake and body weight in rats.\",\n      \"method\": \"Tissue-specific AAV-mediated knockdown of GDF15 in kidney and GFRAL in area postrema, plasma GDF15 measurement, food intake and body weight assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific genetic knockdown at two anatomical sites with defined functional readout\",\n      \"pmids\": [\"37060902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Ketogenic diet activates hepatic PPARγ, which directly binds to the regulatory region of Gdf15, increasing its transcription in hepatocytes. Elevated circulating GDF15 is required for ketogenic diet-mediated weight loss via GFRAL signaling; GDF15- or GFRAL-deficient mice do not lose weight on KD.\",\n      \"method\": \"PPARγ chromatin immunoprecipitation, hepatocyte-specific AAV8 Gdf15 knockdown, GDF15 and GFRAL knockout mice, hepatic Pparγ knockout mice, recombinant GDF15 rescue experiments\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP demonstrating direct PPARγ binding to Gdf15 regulatory region, multiple genetic models with rescue experiments\",\n      \"pmids\": [\"38056430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CNOT6L deadenylase regulates GDF15 expression post-transcriptionally; CNOT6L inhibition stabilizes hepatic Gdf15 mRNA, increasing circulating GDF15 levels which act on the hindbrain to suppress appetite.\",\n      \"method\": \"CNOT6L inhibition, mRNA stability assay, serum protein measurement, food intake assay\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mRNA stabilization mechanism with functional in vivo readout in a single lab\",\n      \"pmids\": [\"35385705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"β-Arrestin1 (ARRB1) interacts with GDF15 precursor (pro-GDF15) and facilitates transportation of pro-GDF15 to the Golgi apparatus for cleavage and maturation. ARRB1 deficiency impairs GDF15 maturation and accelerates steatohepatitis development.\",\n      \"method\": \"Co-immunoprecipitation (ARRB1-GDF15 interaction), Arrb1 knockout mice, pro-GDF15 overexpression rescue experiments, recombinant GDF15 treatment\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP demonstrating physical interaction plus genetic knockout with rescue, single lab\",\n      \"pmids\": [\"31857195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF15 promotes generation of peripherally derived inducible Treg cells and enhances suppressive function of natural Treg cells by interacting with CD48 on T cells, which downregulates STUB1 (an E3 ligase that mediates FOXP3 protein degradation), thereby stabilizing FOXP3 and promoting immunosuppression in HCC.\",\n      \"method\": \"Co-immunoprecipitation (GDF15-CD48 interaction), mass spectrometry, chromatin immunoprecipitation, Gdf15 knockout mouse models, flow cytometry, RNA sequencing\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying CD48 as receptor plus downstream mechanistic pathway with multiple methods, single lab\",\n      \"pmids\": [\"34489334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF15 stimulates melanogenesis in melanocytes through MITF/tyrosinase upregulation via β-catenin signaling, as demonstrated by co-culture experiments with GDF15-overexpressing or GDF15-knockdown fibroblasts.\",\n      \"method\": \"Fibroblast-melanocyte co-culture, GDF15 lentiviral overexpression and shRNA knockdown, melanogenesis assay, ex vivo skin culture\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — co-culture experiment with defined signaling pathway, single lab, no receptor identification\",\n      \"pmids\": [\"32416083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GDF15 promotes cervical cancer cell proliferation via the PI3K/AKT and MAPK/ERK signaling pathways, and GDF15 forms a protein complex with ErbB2 in cervical cancer cells as identified by immunoprecipitation. C-myc trans-activates GDF15 expression by binding E-box motifs in the GDF15 promoter.\",\n      \"method\": \"Immunoprecipitation (GDF15-ErbB2 complex), chromatin immunoprecipitation (C-myc binding to GDF15 promoter), western blotting, MTT assay, in vivo tumor formation\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP with limited mechanistic follow-up, single lab, GFRAL-independent mechanism proposed without full validation\",\n      \"pmids\": [\"29636108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GDF15 promotes epithelial-mesenchymal transition (EMT) and metastasis in colorectal cancer by binding to TGF-β receptor and activating Smad2 and Smad3 signaling pathways.\",\n      \"method\": \"Recombinant GDF15 treatment, TGF-β receptor binding, Smad2/3 phosphorylation assay, in vitro metastasis assays, in vivo xenograft model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, receptor binding claim without full biochemical validation; TGF-β contamination issue noted in PMID 29161287 may confound some GDF15-TGFβR findings\",\n      \"pmids\": [\"26497212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GDF15 inhibits lung fibroblast growth and activation by inactivating the TGF-Smad pathway; GDF15 administration alleviates pulmonary fibrosis in mouse models.\",\n      \"method\": \"Primary fibroblast culture, epithelial cell-conditioned media fractionation, TGF-Smad pathway signaling analysis, mouse lung fibrosis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway analysis without full mechanistic dissection, note potential TGF-β contamination concern\",\n      \"pmids\": [\"29724997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Recombinant GDF15 stimulates α-smooth muscle actin (αSMA) expression in normal human lung fibroblasts, and this fibroblast activation is mediated through the ALK5 (activin receptor-like kinase 5) receptor, not GFRAL, suggesting a GFRAL-independent mechanism in peripheral fibrosis.\",\n      \"method\": \"Recombinant GDF15 treatment of lung fibroblasts, αSMA expression assay, ALK5 receptor inhibitor experiments, 3D spheroid assay, in vivo bleomycin fibrosis model with GDF15 neutralization\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological receptor dissection (ALK5) in vitro combined with in vivo neutralization, single lab with multiple methods\",\n      \"pmids\": [\"35993367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AMPK mediates energetic stress-induced GDF15 expression in mouse liver; direct activation of AMPK β1-containing complexes by A769662 increases hepatic Gdf15 expression and circulating GDF15 independently of ER stress, an effect absent in AMPKβ1-/- mice.\",\n      \"method\": \"AMPKβ1 knockout mice, direct AMPK activators (AICAR, R419, A769662), CHOP knockout mice, hepatic Gdf15 expression and circulating GDF15 measurement\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function (AMPKβ1-/-) with pharmacological dissection of ER-stress independence, single lab\",\n      \"pmids\": [\"33337559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 upregulation by metformin is AMPK-dependent, and GDF15 in turn is required for full AMPK activation by metformin in liver and skeletal muscle independently of CNS/GFRAL signaling, revealing a positive feedback loop between AMPK and GDF15.\",\n      \"method\": \"Gdf15 knockout mice, Gdf15 siRNA knockdown in cultured hepatocytes and myotubes, AMPK activity assays, metformin treatment\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and siRNA-based loss of function with enzyme activity assays, single lab\",\n      \"pmids\": [\"36435271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway; Gdf15-/- mice show overactivated TGF-β1/SMAD3 signaling, reduced hepatic AMPK activity, elevated gluconeogenesis and fibrosis, and recombinant GDF15 reverses these effects in hepatocytes independently of GFRAL.\",\n      \"method\": \"Gdf15 knockout mice, recombinant GDF15 treatment, pharmacological SMAD3 inhibition, primary hepatocyte culture, AMPK and SMAD3 phosphorylation assays\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with recombinant rescue and pharmacological epistasis, single lab\",\n      \"pmids\": [\"38176644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 knockdown in cancer cells decreases SLC7A11 (system Xc- component) expression, promotes erastin-induced ferroptosis, and reduces extracellular glutamate, intracellular GSH, while increasing lipid ROS levels, indicating GDF15 promotes ferroptosis resistance through SLC7A11 upregulation.\",\n      \"method\": \"GDF15 siRNA knockdown, erastin-induced ferroptosis assay, SLC7A11 expression analysis, lipid ROS measurement, GSH quantification\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell line, no receptor or upstream mechanism identified\",\n      \"pmids\": [\"32209255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In the asthma context, Wnt pathway activation downstream of Notch4 in Treg cells induces GDF15 expression, and GDF15 produced by Treg cells activates group 2 innate lymphoid cells (ILC2s), creating a feed-forward mechanism for aggravated airway inflammation.\",\n      \"method\": \"Notch4 conditional knockout, Wnt pathway inhibition, GDF15 expression analysis in Treg cells, ILC2 activation assay\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic pathway dissection with defined cellular mechanism, single lab\",\n      \"pmids\": [\"32929274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF15 apoptotic and cytotoxic effects in A549 lung cancer cells depend on TGFBR2 expression; TGFBR2 silencing blocks GDF15-induced cytotoxicity, apoptosis, caspase-9 and caspase-3 activation, and ERK1/2/p38 MAPK modulation.\",\n      \"method\": \"TGFBR2 siRNA knockdown, GDF15 overexpression, caspase activation assay, annexin V/PI flow cytometry, ERK/p38 phosphorylation\",\n      \"journal\": \"Cell biochemistry and function\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single cell line, single lab; TGFBR2 as a GDF15 receptor is contested (TGF-β contamination issue noted in PMID 29161287)\",\n      \"pmids\": [\"31172564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Pharmacological GDF15 suppresses voluntary wheel running activity (exercise motivation) and feeding via GFRAL-dependent mechanisms, but physiologically induced GDF15 by exercise does not affect appetite or exercise motivation despite reaching similar circulating levels.\",\n      \"method\": \"Recombinant GDF15 administration, GFRAL antagonism, voluntary wheel running assay, exercise intervention in mice and humans, food intake measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — four independent human studies plus mouse pharmacology and GFRAL genetic control, single lab group\",\n      \"pmids\": [\"33589633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 and semaglutide reduce food intake and body weight through largely distinct mechanisms: semaglutide amplifies satiation signals (CCK, ingested food) and inhibits AgRP neurons, while GDF15 induces visceral malaise but does not affect feeding motivation or CCK signal processing; combined treatment produces additive weight loss without enhanced malaise.\",\n      \"method\": \"Progressive ratio operant paradigm, CCK potentiation assay, pica/kaolin intake assay, conditioned food aversion test, fibre photometry of AgRP neurons in vivo\",\n      \"journal\": \"Diabetes, obesity & metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple behavioral and neural circuit assays distinguishing GDF15 vs. semaglutide mechanisms, single lab\",\n      \"pmids\": [\"35129264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GDF15 produced in white adipose tissue macrophages (M2-like) mediates adrenaline/β-adrenergic-induced anxiety-like behavior; genetic deletion of adipose triglyceride lipase or β-adrenergic receptors blocks β-adrenergic-induced GDF15 increases; anxiety-like behavior elicited by adrenaline or restraint stress is eliminated in GFRAL-deficient mice, identifying GDF15-GFRAL as a link between lipolysis and anxiety behavior.\",\n      \"method\": \"ATGL knockout, β-adrenergic receptor knockout, GFRAL knockout mice, restraint stress model, GDF15 measurement in adipose tissue and plasma, anxiety behavioral assays\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic loss-of-function models with defined behavioral readout and tissue-specific origin of GDF15 identified\",\n      \"pmids\": [\"40234625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 promotes liver fibrosis amelioration by reprogramming macrophage metabolism to an oxidative phosphorylation-dependent anti-inflammatory state; adoptive transfer of GDF15-preprogrammed macrophages to fibrotic mice attenuates inflammation and fibrosis.\",\n      \"method\": \"Gdf15 knockout mice, AAV8-mediated GDF15 overexpression, recombinant GDF15 treatment, adoptive macrophage transfer, metabolic pathway analysis in macrophages\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout, overexpression, and adoptive transfer with defined metabolic mechanism, single lab\",\n      \"pmids\": [\"37499753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In sepsis-induced cardiomyopathy, GDF15 activates the ALK5-SMAD2/3 pathway, which inhibits SOCS1 expression, thereby activating the JAK2/STAT3 pathway, promoting GPX4 transcription and inhibiting ferroptosis in cardiomyocytes.\",\n      \"method\": \"Transcriptomic analysis, ALK5-SMAD2/3 signaling pathway assay, SOCS1 expression, JAK2/STAT3 and GPX4 measurements, mouse SIC model with GDF15 antagonism\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway analysis based largely on expression data with limited direct mechanistic validation\",\n      \"pmids\": [\"39147013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GDF15 blockade prevents cachexia and slows the progression of heart failure in a mouse model where PPP1R15A deficiency leads to increased cardiac Gdf15 expression and elevated circulating GDF15, indicating that cardiac stress drives a GDF15-dependent pathway promoting weight loss and worsening cardiac function.\",\n      \"method\": \"GDF15-blocking antibody treatment, PPP1R15A knockout bone marrow reconstitution mouse model, cardiac function assessment, Gdf15 expression analysis\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic model with pharmacological blockade demonstrating pathway requirement, single lab\",\n      \"pmids\": [\"39312445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GDF15 in colorectal cancer cells promotes EMT and metastasis via TGFβR/Smad2/Smad3 pathway activation. GDF15 silencing by shRNA suppresses GDF15-induced cell invasion and migration in LoVo cells.\",\n      \"method\": \"GDF15 overexpression and shRNA knockdown, western blotting for EMT markers (N-cadherin, vimentin, Twist1, E-cadherin), cell invasion/migration assays\",\n      \"journal\": \"Artificial cells, nanomedicine, and biotechnology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell line; TGF-β receptor-mediated mechanism may be confounded by contamination issues\",\n      \"pmids\": [\"29771147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"C-reactive protein (CRP) stimulates GDF15 expression in endothelial cells through p53; CRP treatment of endothelial cells recruits p53 to binding sites in the GDF15 promoter, inducing GDF15 transcription.\",\n      \"method\": \"CRP treatment of human aortic endothelial cells, dual-luciferase reporter assay, chromatin immunoprecipitation (p53 binding to GDF15 promoter), CRP plasmid transfection\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus luciferase reporter assay confirming direct p53 binding to GDF15 promoter, single lab\",\n      \"pmids\": [\"29967567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDF15 in cancer-associated fibroblasts binds GFRAL on melanoma cells, promoting RET phosphorylation, triggering downstream signaling that induces tumor cell stemness and secretion of CCL18 and TGF-β, leading to M2 macrophage polarization and immunosuppressive microenvironment.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter assay, recombinant protein rescue experiments, CRISPR knockout mice, Cre-loxP system mice, cell co-culture\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in a single lab including Co-IP and genetic models\",\n      \"pmids\": [\"40555562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Single nuclei RNA sequencing identified a single population of GFRAL and RET co-expressing excitatory neurons in the area postrema as the primary direct cellular target of GDF15 in the hindbrain; GDF15 treatment induced cell-type-specific transcriptomic changes in these neurons and secondary changes in other neuronal and glial subtypes of the AP/NTS.\",\n      \"method\": \"Single nuclei RNA sequencing of AP and NTS micropunches from GDF15-treated vs. saline-treated rats\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — snRNAseq of ~35,000 nuclei providing cell-type-specific resolution of GDF15's direct targets, single lab\",\n      \"pmids\": [\"34942400\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GDF15 is a stress-induced, furin-cleaved, disulfide-linked dimeric cytokine secreted by diverse cell types that signals primarily through a GFRAL-RET heterodimeric receptor complex exclusively expressed in area postrema and nucleus tractus solitarius neurons of the hindbrain, activating a neural circuit that reduces food intake, triggers aversive/nausea-like responses, activates the HPA axis via GFRAL, and — through a GFRAL-β-adrenergic axis — maintains energy expenditure in skeletal muscle; peripherally, GDF15 promotes adipose lipolysis via a sympathetic axis downstream of GFRAL and modulates macrophage metabolism and immune tolerance (including via a CD48 receptor on T cells in the immune microenvironment), while its transcription is regulated by p53, PPARγ, and the integrated stress response/AMPK pathway, and its maturation requires ARRB1-mediated trafficking to the Golgi.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GDF15 is a stress-induced, secreted dimeric cytokine that signals through a hindbrain receptor system to regulate feeding, energy balance, and stress responses [#2, #3]. It is synthesized as a 62-kDa precursor that is furin-cleaved and secreted as a 25-kDa disulfide-linked dimer [#0], with maturation depending on \\u03b2-arrestin1 (ARRB1)-mediated trafficking of pro-GDF15 to the Golgi [#16]. Its canonical signaling axis requires the high-affinity receptor GFRAL, expressed exclusively in area postrema and nucleus tractus solitarius neurons that co-express the co-receptor RET, where GDF15 drives RET phosphorylation and activates a circuit reaching the parabrachial nucleus and central amygdala to suppress food intake and induce aversive responses [#2, #3, #37, #38]. Through GFRAL this axis also activates the HPA stress axis [#9], counteracts adaptive thermogenesis via a \\u03b2-adrenergic pathway that sustains fatty acid oxidation in skeletal muscle [#12], and drives an adipose sympathetic-lipolytic program linking lipolysis to anxiety-like behavior [#7, #31]. The GDF15-GFRAL axis is the obligate mediator of metformin- and ketogenic-diet-induced weight loss, with GDF15 induced in kidney, intestine, and liver and its transcription controlled by the integrated stress response, AMPK, p53, and PPAR pathways [#5, #13, #14, #6, #23, #36]. GDF15 expression is also tuned post-transcriptionally by the CNOT6L deadenylase [#15]. Beyond the CNS axis, GDF15 reprograms macrophage metabolism toward an anti-inflammatory oxidative state and stabilizes Treg FOXP3 by engaging CD48 on T cells, contributing to immune tolerance [#32, #17]. Reported GFRAL-independent actions in peripheral fibroblasts and hepatocytes engage the ALK5/SMAD pathway [#22, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing how GDF15 becomes a secreted signal: it is produced as an intracellular precursor requiring proteolytic processing and dimerization before release.\",\n      \"evidence\": \"Biochemical characterization of precursor cleavage and secretion\",\n      \"pmids\": [\"9886240\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the trafficking machinery required for maturation\", \"No receptor or downstream signaling defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"First demonstration that GDF15 has direct biological activity, inhibiting hematopoietic progenitor proliferation.\",\n      \"evidence\": \"In vitro proliferation assay with hematopoietic progenitors\",\n      \"pmids\": [\"9375789\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single functional assay with no mechanistic detail\", \"No receptor identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved the central question of how GDF15 signals: GFRAL is its high-affinity receptor, acting with RET co-receptor in restricted hindbrain neurons to mediate appetite and body weight suppression.\",\n      \"evidence\": \"Receptor binding, RET co-receptor identification, GFRAL knockout mice, in vivo pharmacology in mice and primates; replicated across four labs\",\n      \"pmids\": [\"28846097\", \"28846098\", \"28846099\", \"28953886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve peripheral GFRAL-independent actions\", \"Structural basis of the GDF15-GFRAL-RET ternary complex not defined here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Mapped GFRAL signaling to a defined neural circuit and demonstrated its requirement for chemotherapy-induced anorexia, framing GDF15 as an 'emergency' stress-feeding regulator.\",\n      \"evidence\": \"Neuronal activation mapping, GFRAL knockout mice, chemotherapy-induced anorexia model; crystal structure and gastric emptying assays\",\n      \"pmids\": [\"28953886\", \"29046435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type resolution of direct targets not yet defined\", \"Downstream effector neurons of PBN/CeA circuit incompletely mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established the trafficking step needed for maturation: ARRB1 binds pro-GDF15 and routes it to the Golgi, linking maturation defects to steatohepatitis.\",\n      \"evidence\": \"Co-IP, Arrb1 knockout mice, pro-GDF15 rescue experiments\",\n      \"pmids\": [\"31857195\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP for the ARRB1-GDF15 interaction\", \"Whether ARRB1 acts on all GDF15-producing tissues unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected GDF15 to clinical pharmacology by showing the GDF15-GFRAL axis is required for metformin-induced weight loss, and tied GDF15 induction to the integrated stress response.\",\n      \"evidence\": \"Human RCTs, GDF15 and GFRAL knockout mice, GFRAL-antagonist antibody, dietary models, conditioned taste aversion\",\n      \"pmids\": [\"31875646\", \"30639358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue source of metformin-induced GDF15 not fully resolved at this stage\", \"Molecular link between ISR sensors and Gdf15 transcription not detailed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended GFRAL signaling beyond feeding to endocrine stress, showing GDF15 activates the HPA axis and is required for stress-toxin-induced corticosterone responses.\",\n      \"evidence\": \"GDF15 administration with GFRAL-blocking antibody, Gdf15 knockout mice, multiple stress models, corticosterone readout\",\n      \"pmids\": [\"34187898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Circuit linking GFRAL neurons to HPA axis not mapped\", \"Physiological stressors driving endogenous response incompletely defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a peripheral effector branch: GFRAL activation drives a sympathetic-lipolytic axis in adipose tissue, and a GFRAL antagonist blocks GDF15-driven RET recruitment.\",\n      \"evidence\": \"Antagonistic antibody, chemical sympathectomy, ATGL knockout mice, adipose gene expression, tumor-bearing models\",\n      \"pmids\": [\"32661391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a hindbrain receptor produces sympathetic output to adipose not fully mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed GDF15 maintains energy expenditure against caloric-restriction-induced adaptive thermogenesis via a GFRAL-\\u03b2-adrenergic axis acting on skeletal muscle.\",\n      \"evidence\": \"Recombinant GDF15, caloric restriction, fatty acid oxidation and calcium futile cycling assays in muscle\",\n      \"pmids\": [\"37380764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of intermediary neurons relaying GFRAL signal to muscle unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Refined the source of metformin-induced GDF15 to the kidney and confirmed dual-site (kidney GDF15, area postrema GFRAL) requirement for drug action.\",\n      \"evidence\": \"Tissue-specific AAV knockdown of GDF15 in kidney and GFRAL in area postrema in rats\",\n      \"pmids\": [\"37060902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of metformin-driven renal GDF15 induction not detailed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified hepatic PPAR\\u03b3 as a direct transcriptional driver of Gdf15 mediating ketogenic-diet weight loss through GFRAL.\",\n      \"evidence\": \"PPAR\\u03b3 ChIP, hepatocyte-specific Gdf15 knockdown, GDF15/GFRAL/hepatic PPAR\\u03b3 knockouts, recombinant rescue\",\n      \"pmids\": [\"38056430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between PPAR\\u03b3 and other Gdf15 regulators (p53, AMPK) not integrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined transcriptional and feedback control of GDF15 expression through p53, PPAR\\u03b2/\\u03b4-AMPK, and energetic stress sensing.\",\n      \"evidence\": \"ChIP/luciferase for p53 (CRP-induced), PPAR\\u03b2/\\u03b4 epistasis, AMPK\\u03b21 knockout mice with direct activators\",\n      \"pmids\": [\"29967567\", \"34380027\", \"33337559\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each pathway in vivo unclear\", \"Direct AMPK-to-Gdf15 transcriptional link not fully defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a positive feedback loop in which GDF15 is needed for full AMPK activation by metformin in liver and muscle independently of GFRAL, and uncovered CNOT6L as a post-transcriptional regulator.\",\n      \"evidence\": \"Gdf15 knockout/siRNA, AMPK assays, metformin; CNOT6L inhibition with mRNA stability assay\",\n      \"pmids\": [\"36435271\", \"35385705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GFRAL-independent peripheral receptor for the AMPK feedback not identified\", \"Direct CNOT6L target site on Gdf15 mRNA not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established GDF15 as an immunomodulator, stabilizing Treg FOXP3 by engaging CD48 on T cells and downregulating STUB1.\",\n      \"evidence\": \"Co-IP, mass spectrometry, ChIP, Gdf15 knockout, flow cytometry, RNA-seq in HCC\",\n      \"pmids\": [\"34489334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CD48 as a functional GDF15 receptor needs reciprocal validation\", \"Relationship to canonical GFRAL signaling unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated GDF15 reprograms macrophages toward an anti-inflammatory oxidative-phosphorylation state, attenuating liver fibrosis.\",\n      \"evidence\": \"Gdf15 knockout, AAV8 overexpression, recombinant GDF15, adoptive macrophage transfer, metabolic profiling\",\n      \"pmids\": [\"37499753\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating macrophage effect not identified\", \"Single-disease context\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked peripheral lipolysis to behavior, showing adipose-macrophage-derived GDF15 mediates \\u03b2-adrenergic-induced anxiety via GFRAL.\",\n      \"evidence\": \"ATGL, \\u03b2-adrenergic receptor, and GFRAL knockout mice, restraint stress, anxiety assays, tissue GDF15 measurement\",\n      \"pmids\": [\"40234625\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Circuit translating GFRAL activation into anxiety behavior not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved cell-type resolution of GDF15's central target as a single GFRAL/RET co-expressing excitatory AP neuron population.\",\n      \"evidence\": \"Single nuclei RNA sequencing of AP/NTS from GDF15-treated rats\",\n      \"pmids\": [\"34942400\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional dissection of transcriptomic changes not performed\", \"Secondary glial/neuronal effects not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguished pharmacological from physiological GDF15 and from GLP-1 agonism: GDF15 induces malaise without altering feeding motivation, and physiological exercise-induced GDF15 does not affect appetite.\",\n      \"evidence\": \"Operant paradigms, CCK potentiation, pica/aversion tests, AgRP fibre photometry, human exercise studies\",\n      \"pmids\": [\"33589633\", \"35129264\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why physiological and pharmacological GDF15 differ despite similar levels unresolved\", \"Single lab group for the mechanistic comparison\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Characterized GFRAL-independent peripheral actions through ALK5/SMAD signaling in fibroblasts and hepatocytes, with context-dependent pro- and anti-fibrotic outcomes.\",\n      \"evidence\": \"ALK5 inhibitor and SMAD3 inhibition, recombinant GDF15, Gdf15 knockout and bleomycin/SIC/PPP1R15A disease models\",\n      \"pmids\": [\"35993367\", \"38176644\", \"39147013\", \"39312445\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ALK5/TGF\\u03b2R binding contested due to possible TGF-\\u03b2 contamination\", \"Reconciliation with GFRAL-restricted canonical model not achieved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how GDF15 exerts its reported GFRAL-independent peripheral effects mechanistically, including the identity of any peripheral receptor and validation of CD48 and ALK5/TGF\\u03b2R engagement.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No validated GFRAL-independent receptor\", \"TGF\\u03b2R/ALK5 claims confounded by contamination concerns\", \"CD48 interaction lacks reciprocal validation\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 3, 37]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 9, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 12]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 12, 14, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [17, 32]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [6, 9, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GFRAL\", \"RET\", \"ARRB1\", \"CD48\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}